Phase 3 TNBC Clinical Trials

7 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–7 of 7 trials

Recruiting

Phase 3

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer(TNBC)

Akeso416 enrolled1 locationNCT06767527

Recruiting

Phase 3

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

TNBC - Triple-Negative Breast Cancer

West China Hospital318 enrolled1 locationNCT06627712

Recruiting

Phase 3

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer(TNBC)

Qilu Pharmaceutical Co., Ltd.504 enrolled1 locationNCT06732323

Recruiting

Phase 3

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Triple Negative Breast Cancer(TNBC)Breast Cancers

UNICANCER2,454 enrolled2 locationsNCT06606730

Recruiting

Phase 3

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

Fudan University606 enrolled1 locationNCT05862064

Recruiting

Phase 3

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Triple Negative Breast Cancer(TNBC)

Biotheus Inc.360 enrolled70 locationsNCT06419621

Recruiting

Phase 3

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

Fudan University424 enrolled2 locationsNCT05999149